Anzeige
Mehr »
Login
Donnerstag, 28.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Spezial am Donnerstag: Rallye II. - Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EHM3 | ISIN: US92337C2035 | Ticker-Symbol: 2VSA
Tradegate
27.03.24
12:21 Uhr
10,600 Euro
-0,300
-2,75 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
VERASTEM INC Chart 1 Jahr
5-Tage-Chart
VERASTEM INC 5-Tage-Chart
RealtimeGeldBriefZeit
11,10011,20016:59
11,10011,20016:26

Aktuelle News zur VERASTEM Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
20.03.Verastem director sells over $4k in company stock3
18.03.Verastem, with FDA filing imminent, shows toll rare cancer takes on wellbeing2
14.03.Verastem Inc reports results for the quarter ended in December - Earnings Summary1
14.03.Recap: Verastem Q4 Earnings1
14.03.Verastem GAAP EPS of -$1.02 misses by $0.211
14.03.Verastem, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
14.03.Verastem, Inc. - 10-K, Annual Report1
14.03.Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates38BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the three...
► Artikel lesen
06.03.Verastem gets FDA orphan drug status for low-grade ovarian cancer therapy2
06.03.Verastem Oncology Granted FDA Orphan Drug Designation For Avutometinib In Ovarian Cancer5
29.01.Verastem, Inc. - 8-K, Current Report6
22.01.Verastem (VSTM) Up 8% on Fast Track Tag for NSCLC Combo Therapy8
19.01.Verastem, Inc. - 8-K, Current Report1
19.01.FDA grants fast track designation for Verastem's NSCLC therapy3
19.01.Verastem: Avutometinib Combination Receives Fast Track Designation For KRAS G12C-Mutant NSCLC407THOUSAND OAKS (dpa-AFX) - Verastem (VSTM) said that the U.S. Food and Drug Administration has granted Fast Track Designation to Verastem Oncology's investigational RAF/MEK clamp, avutometinib...
► Artikel lesen
19.01.Verastem rises on FDA's 'fast track' tag for lung cancer combo therapy4
18.01.Verastem gets FDA fast track status for lung cancer drug combo2
18.01.NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders194BELTSVILLE, Md., Jan. 18, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines...
► Artikel lesen
08.01.Verastem, Inc. - 8-K, Current Report4
13.12.23Verastem starts Phase 3 study for ovarian cancer drug combination5
Seite:  Weiter >>
40 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1